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ABSTRACT 
BACKGROUND 
Older reports ofuse of hydrochloric acid (HCl) infusions for treatment of metabolic alkalosis 
document variable dosing strategies and risk.  
OBJECTIVES: 
This study sought to characterize use of HCl infusions in surgical intensive care unit (SICU) 
patients for the treatment of metabolic alkalosis.   
METHODS: 
Thisretrospective review included patients who received a HCl infusion for > 8 hours. The 
primary endpoint was to evaluate the utility of common acid-base equations for predicting HCl 
dose requirements. Secondary endpoints evaluated adverse effects, efficacy, duration of therapy, 
and total HCl dose needed to correct metabolic alkalosis. Demographics, potential causes of 
metabolic alkalosis, fluid volume, duration of diuretics, and laboratory data were collected.  
RESULTS: 
Thirty patients were included, and the average HCl infusion rate was 10.5± 3.7 mEq/h for an 
average of 29± 14.6 hours. Metabolic alkalosis was primarily diuretic-induced (n = 26). Efficacy 
was characterized by reduction in themedian total serum CO2 from 34 to 27 mM/L 
(p<0.001).The change in chloride ion deficit and change in apparent strong ion difference 
(SIDa)were not correlated with total HCl administered. There were no documented serious 
adverse effects related to HCl infusions. 
CONCLUSION: 
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HCl was effective for treating metabolic alkalosis, and no serious adverse events were seen.In 
this clinical setting, thebaseline chloride ion deficit and SIDawere not useful for prediction of 
total HCl dose requirement, and serial monitoring of response is recommended. 
 
 6 
INTRODUCTION 
The use of hydrochloric acid (HCl) for the treatment of metabolic alkalosis has been 
reported in the literature since the 1960’s. The reported dosing strategies and risk of adverse 
effects varied. HCl infusions are typically used in severe or refractory metabolic alkalosis, and 
are rarely recommended as an initial treatment option. At the University of Rochester Medical 
Center (URMC), the use of HCl is primarily in the management of mild to moderate metabolic 
alkalosis, typically without alkalemia, secondary to use of continuous infusion of chloruretic, 
loop diuretics.At our institution,intravenous HCl is the treatment of choice for surgical intensive 
care unit (SICU) patients with diuretic-induced chloride depletion alkalosis that have poor or 
limited response to acetazolamide, that occurs in patients with concomitant renal failure, or is 
associated with a markedly elevated total serum CO2(tCO2) (e.g. >38mM/L). 
HCl is not commercially available and must be extemporaneously compounded from 
concentrated, sterilized HCl solution. At our institution, the HCl is added to sterile water for 
injection in glass containers using Millex-FG 0.2micron hydrophobic filters (Merck Millipore 
Ltd, Cork, IRL), which are specifically designed for acids and are chemically safe, utilizing a 
Biohazard Safety Cabinet (Vertical Flow BSC) with appropriate Personal Protective 
Equipment.Dose requirementsare typically based on the patient’s base excess or chloride ion 
deficit. Typical concentrations are 0.1 or 0.2 N (100-200 mmol Cl-/L). Concentrations greater 
than 0.2 N have been associated with hemolysis, and are therefore not recommended.1-4 Infusions 
of HCl have been well-tolerated when administered through the distal port of a central 
intravenous catheter1-20, with only rare reports of significant tissue necrosis emphasizing the need 
to confirm the proper placement of central catheters prior to infusion.21-23At our institution, HCl 
infusions are typically stopped based on clinical judgement and close monitoring of individual 
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response, (e.g., when the underlying cause of the metabolic alkalosis is removed or resolved and 
the acid-base disturbance is corrected). Ongoing monitoring includes CBC and electrolytes, 
blood gases, and vigilant observationof the infusion site and surrounding tissues. 
The purpose of this retrospective study was to summarize and evaluate our experience 
with the use of intravenous HCl in SICU patients with a focus on evaluating the utility of 
common acid-base equations for predicting total HCl dose requirements.We also evaluated the 
effectiveness, safety, and indication for HCl therapy.This study was approved by and conducted 
in compliance withrequirements ofthe University of Rochester Institutional Review Board, and 
informed consent was waived. 
MATERIALS AND METHODS 
A retrospective review of the medical record was completed for all patients who received 
greater than 8 hours of HCl infusion whileadmitted to theSICU service from January 1st, 2004 to 
December 31st, 2005. Patients were identified by querying the pharmacy records for the 
manufacturing and dispensing of HCl during the timeframe stated above.   
Demographic information was collected including age (if greater than 90 years, we 
recorded >90), gender, height, weight, and race or ethnic group. Primary reason for ICU 
admission, and potential causes of and contributors to metabolic alkalosis were recorded. The 
total input and output of fluids during the ICU admission, as recorded on daily flow sheets, were 
calculated up to the point of the initiation of diuresis. The duration and dose of loop diuretics 
administered were collected along with total input and output of fluids during the exposure to 
diuretics. The volume of gastric secretions lost via nasogastric (NG) tube was recorded. Total 
blood products received from the time of admission until 24 hours after the conclusion of the 
HCl infusion were recorded. All available laboratory values were recorded starting at the 
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initiation of diuresis and continuing through 24 hours after the conclusion of the HCl infusion. 
These values include chemistries (sodium, chloride, creatinine, phosphate, corrected ionized 
calcium, albumin, potassium, total carbon dioxide, blood urea nitrogen, magnesium, lactate, and 
lactate dehydrogenase) and arterial blood gases (pH, pCO2, pO2, and bicarbonate). Hematologic 
parameters were also collected (hemoglobin, hematocrit, abnormal RBC morphology). The 
infusion rate, total dose and incremental doses of HCl were recorded. The incremental doses of 
HCl corresponded with the times of the serial laboratory values available for the patient. For 
each set of laboratory data that provided adequate data,chloride ion deficit and apparent strong 
ion difference (SIDa) were calculated.The following equations were used to calculate SIDa and 
chloride ion deficit: 
 
SIDa = (Na+ + K+ + Ca2+ + Mg2+) – (Cl- + lactate-) 
 
Chloride Ion Deficit = (0.2 L/kg x body weight (kg)) x ([Cl-] Normal - [Cl-] Corrected)                                                      
[Cl-] corrected = [Cl-] observed x ([Na+] normal/[Na+] observed) 
[Cl-] Normal = 103 mM/L; [Na+] Normal = 140 mM/L 
 
Any adverse effects from the HCl infusion, as documented in the medical record, were 
recorded. In addition, any biochemical evidence of adverse events including moderate to severe 
metabolic acidosis (tCO2<15mM/L, or arterial pH <7.25), or laboratory findings consistent with 
red blood cell hemolysis were recorded. 
All data are reporting using appropriate descriptive statistics.  Comparison of results before 
and after HCl infusion were completed using Wilcoxon signed ranks test. The relationship 
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betweenSIDa or chloride ion deficit and total HCl dose were evaluated using simple linear 
regression analysis. All analyses were considered descriptive and exploratory, and no sample 
size or power analysis were conducted. 
RESULTS 
The results of the pharmacy database query found records for 32 patients who had orders 
for HCl infusions. One patient never received the HCl infusion (unknown reason) and one 
patient failed to meet the inclusion criteria of >8 hours of total infusion time.Therefore, 30 
patients were included in this study.Demographic information for the 30 patients is presented in 
Table 1. 
The mean totalmilliequivalents (mEq) of HCl received, the total duration of the infusion, 
and average mEq/h for each patientis provided inTable 1. The average HCl infusion rate was 
10.5 ± 3.7 mEq/h (4to 16.6 mEq/h). The average duration of the HCl infusion was 29.0± 14.6 
hours(9 to 68 hours). 
The potential causes of metabolic alkalosis were evaluated for each patient who received a 
HCl infusion. Twenty-six patients were infused with HCl following sustained loop diuretic 
therapy, 3 patients following large blood product administration (>20 units of blood products 
received prior to HCl infusion), and 1 patient with an unknown mechanism for metabolic 
alkalosis (no loop diuretic administered, no significant NG losses, and no blood products 
received). Patients were primarily general surgery, vascular surgery, and liver transplant patients. 
Figure 1illustrates the change of total carbon dioxide (tCO2)from pre- to post-HCl infusion 
which was characterized by a reduction in the median tCO2 from 34 to 27 mM/L (p<0.001). 
The total HCl administered was not correlated with the change in chloride ion deficit. 
There was also no significant association betweentotal HCl administered and change in SIDa. 
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There were no serious adverse effects documented in the medical record related to the HCl 
infusions. There were no documented cases of tissue necrosis or extravasation injuries. There 
were no cases of moderate to severe metabolic acidosis (pH < 7.25 or tCO2< 15 mM/L) during or 
following the HCl infusion. Evaluation of CBC results including microscopy during the HCl 
infusions revealed no evidence of hemolysis. 
DISCUSSION 
Metabolic alkalosisis a common, if not relatively overlooked, finding in critically ill 
patients, and may present with concomitant metabolic acidosis. This acid-base disorder 
isclassically described as being either “chloride responsive” or “chloride resistant”, with 
hypochloremic, hyperbicarbonatemic alkalosis (“chloride responsive”) being the predominant 
form seen in the ICU. This form of metabolic alkalosis is also referred to as chloride-depletion 
metabolic alkalosis (CDA). The most common underlying causes of CDA in the critically ill are 
loss of HCl from gastric secretions (vomiting or large volume NG aspiration of gastric contents) 
and the administration of chloruretic diuretics (urinary excretion of excess ammonium chloride). 
Other contributing factors may include delayed or incomplete recovery from hypercapnic 
acidosis, large volume blood transfusion, administration of alkali, and liver failure.24-26 
The critically ill surgical patient often requires aggressive volume resuscitation in the 
early hours to days of their care in the ICU to maintain organ perfusion and decrease the risk of 
multiple organ failure. Once the patient is hemodynamically stable, off all vasopressor support, 
and no longer requiring volume resuscitation, relatively aggressive diuretic therapy is often 
initiated. The goals of this therapy include promoting the loss of excess extracellular fluid and 
shortening the time to extubation and transfer out of the ICU, thereby avoiding adverse sequelae 
associated with prolongedmechanical ventilation and extended ICU stays. At our site, diuresis is 
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most commonly achieved by administering a continuous infusion loop diuretic to maximize 
diuretic efficacy and efficiency and achieve the greatest overall net fluid loss. One of the most 
common complications that limit the extent of diuresis is the development of a “contraction 
alkalosis” with elevation of tCO2 to >30 mM/L, without other clinical evidence of intravascular 
volume depletion. Effective treatment of this CDA will often allow continued diuresis. 
Administration of sodium chloride in the form of crystalloid IV solutions would be an effective 
treatment for CDA but is counterproductive to removing the excess extracellular fluid and 
facilitating weaning from mechanical ventilation. Many ICU patients will not tolerate large doses 
of potassium chloride to reverse the chloride deficit. Ammonium chloride or arginine 
monochloridehave been recommended in the past, but are often a poor choice in patients with 
underlying liver or renal disease and are no longer commercially available. 
Alternative treatment options for ICU patients with diuretic-induced CDA include 
acetazolamide and hydrochloric acid.24-30 Acetazolamide has shown to be effective in reducing 
hyperbicarbonatemia in critically ill patients with mild to moderate metabolic alkalosis27-30,and is 
often used as a first-line agent for the treatment of diuretic-induced CDA. Typical practice at our 
institution is to administer at least 2 doses of acetazolamide (e.g., 500mg daily x 2 days) before 
consideration is given to starting an HCL infusion. In our experience, with continued 
administration of the loop diuretic infusion, acetazolamide has a moderate and short-lived effect 
on reducing tCO2. It is relatively slow to work with nadir tCO2 observed at 16-24 hours after the 
dose29, 30,and is relatively ineffective in the setting of significant renal insufficiency. 
Advantages of HCl therapy include a direct correction of the underlying chloride 
deficiency, no need for end organ metabolism or elimination, titration of the infusion rate to a 
desired tCO2, the ability to stop the treatment when goals are achieved, and the low cost of the 
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infusion. Disadvantages include the lack of a commercially available preparation, necessitating 
expertise and capabilities in manufacturing of sterile IV solutions, and the risk of serious 
extravasation injury. 
Intravenous HCl is considereda treatment option for SICU patients at our institution with 
diuretic-induced CDA that have a poor or limited response to acetazolamide, concomitant renal 
failure, or a markedly elevated tCO2 (e.g. >38 mM/L). The use of HCl infusions has been 
reported in the literature for more than 40 years, however most reports discuss its use in severe or 
refractory metabolic alkalosis1-20, 22with only a few authors advocating it as a rational 
earliertreatment option3, 6, 18. There are no reports in the literature describing the use of HCl 
infusion consistent with our application to reverse diuretic-induced CDA with the clinical intent 
of permitting continued diuresis of a patient without clinical evidence of intravascular volume 
depletion. This study was not of adequate design nor intended to evaluate the efficacy of HCl to 
permit continued diuresis or shorten time of mechanical ventilation, but was limited to evaluating 
the biochemical response to treatment. 
Limitations of this study are consistent with it being a single-center, retrospective chart 
review, including the potential for missing or inadequately documented information in the 
medical record.A total of 30 patients were reviewed which therefore limited our ability to 
evaluate the relationship between laboratory parameters and total dose of HCl. In addition, many 
of the patients continued to receive chloruretic diuretics during the HCl infusion period which 
would limit the predictive value of baseline laboratory data for estimating the total HCl infusion 
dose needed to correct hyperbicarbonatemia. Not all patients had ideal laboratory parameters to 
calculate a pre-versus post-HCl infusion SIDa or chloride ion deficit since we had to use the data 
closest to the start and stop of the HCl infusion based upon routine clinical monitoring as 
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opposed to accurately timed samples relative to the infusion. In future prospective studies, a 
complete laboratory work up, including necessary values for SIDa and chloride ion deficit, 
immediately prior to initiation of HCl therapy, at frequent times during the infusion, and 12-24 
hours following completion of the infusion is recommended. The lack of association between the 
chloride ion deficit and HCl dose is also likely related to other fluid loses and other potential 
sources of chloride.  
There are reported casesin the literature of chest wall necrosis21, 23with one fatal 
outcome21 following HCl infusion therapy. There was no documented clinical or laboratory 
evidence of safety issues with HCl therapy in our patient sample, however, given the small 
sample size, any conclusions about the overall safety of this therapy cannot be stated with 
confidence. To reduce the risk of extravasation and tissue injury, it is recommended that HCl 
only be infused using a central venous catheter, that the location of the catheter be confirmed 
radiographically prior to the start of the infusion, and that the HCl solution be infused using the 
most distal port of the catheter. 
CONCLUSIONS 
In this case series, HCl infusions were associated with a significant reduction in tCO2for 
SICU patients with predominantly diuretic-induced metabolic alkalosis, and no serious adverse 
events were observed.The total mEq of HCl received was not correlated with changes in SIDaor 
chloride ion deficit suggesting their limited predictive value. Therefore, routine and frequent 
monitoring of response and adjustment of the infusion rate are recommended for the safe use of 
HCl infusions.  It is also strongly recommended that a firm policy be in place for the use of HCl 
including that it is only infused through the distal port ofa properly placed central venous 
catheter. 
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Table 1. Demographic Data and Results 
 
 
 
 
 
 
 
 
 
  
Number of patients 30 
Age, years (median, range) 65 (23-84) 
Male (%) 19 (63.3%) 
Race: (%) 
Caucasian 
African American 
Native American 
 
27 (90) 
2 (6.7) 
1 (3.3) 
Causes of Metabolic Alkalosis: (%) 
Loop Diuretics 
Blood product transfusions 
Unknown 
 
26 (86.7) 
3 (10) 
1 (3.3) 
pH (median, range)a 7.5 (7.36-
7.59) 
CO2, mmol/L (median, range)a 34 (28-42) 
pCO2, mmHg (median, range)a 45 (30-65) 
Apparent Strong Ion Difference (SIDa), (mean, SD)a 46.6 (3.5) 
SCr, mg/dL (mean, SD)a 1.3 (0.7) 
HCl Infused, mEq (mean, SD) 289 (168) 
Duration of HCl Infusion, h (mean, SD) 29 (14.6) 
Average Infusion Rate, mEq/h (mean, SD) 10.5 (3.7) 
a. At initiation of Hydrochloric acid infusion 
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Figure 1. 
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FIGURE LEGEND 
 
Figure 1. Box plot of total serum CO2 (tCO2) at the start and end of the hydrochloric acid (HCl) 
infusion. The horizontal line in the box represents the median, the interquartile range is 
represented by the box, and the whiskers are the 10th and 90th percentiles. 
 
 
  
